- Home
- BFH vs CELC Comparison
BFH vs CELC Comparison
Compare BFH & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFH | CELC |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2000 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BFH | CELC |
|---|---|---|
| Price | $79.27 | $116.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | $72.25 | ★ $107.88 |
| AVG Volume (30 Days) | 580.8K | ★ 661.2K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 98.36 | N/A |
| EPS | ★ 10.89 | N/A |
| Revenue | ★ $4,521,400,000.00 | N/A |
| Revenue This Year | $53.25 | N/A |
| Revenue Next Year | $3.58 | $740.70 |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.57 | $9.50 |
| 52 Week High | $82.03 | $125.00 |
Technical Indicators
Market Signals| Indicator | BFH | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 54.89 |
| Support Level | $68.65 | $99.38 |
| Resistance Level | $79.10 | $117.61 |
| Average True Range (ATR) | 2.42 | 6.22 |
| MACD | 0.64 | 0.96 |
| Stochastic Oscillator | 90.55 | 68.63 |
Price Performance
Historical ComparisonAbout BFH Bread Financial Holdings Inc.
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.